Antitumor agent-36 exhibits potent antiproliferative and antimetastatic activities; induces severe DNA damage, leading to upregulation of γ-H2AX and p53; promotes tumor cell apoptosis via the mitochondrial apoptotic pathway involving Bcl-2/Bax/caspase-3; and enhances antitumor immune responses by inhibiting PD-L1 expression and increasing infiltration of CD3+ and CD8+ T cells in tumor tissues.